This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 20, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

November 30, 2025

Conditions
Obesity &Amp; Overweight
Interventions
DRUG

Rifampin + VCT220

Participants will receive a single oral dose of VCT220 160 mg on Day 1. Rifampin 600 mg will be administered once daily from Day 4 to Day 10 and from Day 12 to Day 14. On Day 11, rifampin 600 mg will be administered followed 30 minutes later by VCT220 160 mg. All doses are administered under fed or fasting conditions with standardized restrictions on fluid and food intake.

DRUG

Itraconazole + VCT220

Participants will receive a single oral dose of VCT220 40 mg on Day 1. Itraconazole 200 mg will be administered once daily from Day 4 to Day 11 and from Day 13 to Day 14. On Day 12, VCT220 40 mg will be co-administered with itraconazole 200 mg after breakfast. All doses are administered under fed conditions with standardized fluid and fasting controls.

Trial Locations (1)

250014

The First Affiliated Hospital of Shandong First Medical University, Jinan

All Listed Sponsors
lead

Vincentage Pharma Co., Ltd

INDUSTRY